Issue navigation
Volume 20, Issue suppl_6, November 2018
Abstracts from the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology November 15 – 18, 2018 New Orleans, Louisiana
NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi191, https://doi.org/10.1093/neuonc/noy148.792
NIMG-69. CHANGES IN SIGNAL INTENSITY RATIOS OF GLOBUS PALLIDUS AND DENTATE NUCLEUS ON UNENHANCED T1-WEIGHTED IMAGES AFTER MULTIPLE ADMINISTRATIONS OF MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENTS IN BRAIN TUMOR PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi191, https://doi.org/10.1093/neuonc/noy148.793
TMIC-53. IDENTIFICATION OF MYELOID CELL-DERIVED TRANSCRIPTS IN GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi268, https://doi.org/10.1093/neuonc/noy148.1112
Full SNO 2018 Abstracts PDF
Abstracts from the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology November 15 – 18, 2018 New Orleans, Louisiana
Abstracts from the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology November 15 – 18, 2018 New Orleans, Louisiana
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page NP, https://doi.org/10.1093/neuonc/noy148
Abstracts
Abstracts from the 3rd CNS Anticancer Drug Discovery and Development Conference
CADD-04. NANOPARTICLE DELIVERY OF miRNAs TO INHIBIT GBM STEM CELLS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi277, https://doi.org/10.1093/neuonc/noy148.1153
CADD-05. A NEW BIOANALYTICAL METHOD AND SINGLE-DOSE PHARMACOKINETICS FOR OXALOACETATE
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi277–vi278, https://doi.org/10.1093/neuonc/noy148.1154
CADD-09. TARGETING Nrf2 ANTIOXIDATIVE PATHWAY AS A NOVEL THERAPEUTIC STRATEGY FOR IDH1-MUTATED CANCERS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi278, https://doi.org/10.1093/neuonc/noy148.1156
CADD-19. PAM-OBG: A MAOB-SPECIFIC PRODRUG INHIBITOR OF O6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) THAT SENSITIZES GMB TO BCNU/CCNU
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi279–vi280, https://doi.org/10.1093/neuonc/noy148.1164
CADD-21. PROTEASOME INHIBITION IS A TARGETED THERAPY FOR PTEN-DEFICIENT GLIOBLASTOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi280, https://doi.org/10.1093/neuonc/noy148.1165
CADD-23. PD-L1 CHECKPOINT BLOCKADE USING A SINGLE-CHAIN VARIABLE FRAGMENT TARGETING PD-L1 DELIVERED BY RETROVIRAL REPLICATING VECTOR (TOCA 521) ENHANCES ANTI-TUMOR EFFECT IN CANCER MODELS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi280, https://doi.org/10.1093/neuonc/noy148.1166
CADD-26. SMALL MOLECULE EPIGENETIC TARGETING OF METHYL-CPG BINDING PROTEIN 2 (MBD2) FOR MEDULLOBLASTOMA THERAPY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi280, https://doi.org/10.1093/neuonc/noy148.1167
CADD-27. G-QUADRUPLEX DNA DRIVES GENOMIC INSTABILITY AND REPRESENTS A TARGETABLE MOLECULAR ABNORMALITY IN ATRX-DEFICIENT MALIGNANT GLIOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi280, https://doi.org/10.1093/neuonc/noy148.1168
CADD-32. MECHANISMS OF ENHANCED DRUG DELIVERY IN BRAIN TUMORS WITH FOCUSED ULTRASOUND-INDUCED TRANSIENT BLOOD-TUMOR BARRIER DISRUPTION
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi281, https://doi.org/10.1093/neuonc/noy148.1172
CADD-50. AN OLD STORY (MGMT) IN AN EXPANDED CONTEXT (NATIONAL CANCER DATABASE)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi282–vi283, https://doi.org/10.1093/neuonc/noy148.1178
CADD-03. A VERSATILE AND MODULAR TARGETED NANOPARTICLE PLATFORM FOR DELIVERY OF COMBINATION THERAPIES TO ADULT AND PEDIATRIC CNS TUMORS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi277, https://doi.org/10.1093/neuonc/noy148.1152
CADD-06. VISMODEGIB LOADED POLYOXAZOLINE (POx) MICELLES ENHANCE EFFICACY OF VISMODEGIB AND PROLONG MICE SURVIVAL, EMPHASIZE POTENTIAL OF POx MICELLES TO IMPROVE DRUG DELIVERY TO BRAIN TUMORS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi278, https://doi.org/10.1093/neuonc/noy148.1155
CADD-13. COMBINED INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND POLY (ADP-RIBOSE) POLYMERASE (PARP) IMPAIRS GLIOBLASTOMA CELL GROWTH
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi278, https://doi.org/10.1093/neuonc/noy148.1158
CADD-16. DUAL PI3K/Akt INHIBITION TO OVERCOME THE P-gp/BCRP DRUG EFFLUX SYSTEM FOR IMPROVED DRUG DELIVERY IN GLIOBLASTOMA THERAPY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi279, https://doi.org/10.1093/neuonc/noy148.1161
CADD-31. CD97 PERTUBATION BY NOVEL FUSION PROTEIN DAF-FC INHIBITS GBM INVASION AND INDUCES ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi281, https://doi.org/10.1093/neuonc/noy148.1171
CADD-35. THE DEVELOPMENT OF PERSONALIZED CAM AVATAR MODEL TO PREDICT CHEMOTHERAPEUTIC DRUG SENSITIVITY/RESISTANCE OF GLIOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi282, https://doi.org/10.1093/neuonc/noy148.1174
CADD-42. EFFICACY OF MUTANT INTERLEUKIN-13 ALPHA-2 RECEPTOR–TARGETED LIPOSOMAL DOXORUBICIN IN THE INTRACRANIAL BRAIN TUMOR MODEL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi282, https://doi.org/10.1093/neuonc/noy148.1175
CADD-55. LOW SERUM 25 (OH) VITAMIN D LEVEL IS ASSOCIATED WITH INCREASED RISK OF PRIMARY CNS MALIGNANCY: A RETROSPECTIVE COHORT STUDY IN A VETERAN POPULATION
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi283, https://doi.org/10.1093/neuonc/noy148.1180
CADD-57. THE EFFICACY OF THERAPY WITH ABT-414, AN EGFR-TARGETING ADC, IS POTENTIALLY ALTERED BY HETEROZYGOUS DELETION OF THE ENDOCYTIC TRAFFICKING REGULATOR RBSN
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi283–vi284, https://doi.org/10.1093/neuonc/noy148.1182
CADD-10. 2-HYDROXYOLEIC ACID, A NOVEL MEMBRANE LIPID REGULATOR, DEMONSTRATES CLINICAL ACTIVITY IN HIGH-GRADE GLIOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi278, https://doi.org/10.1093/neuonc/noy148.1157
CADD-14. TARGETING THE CD200 CHECKPOINT FOR THE FIGHT AGAINST CENTRAL NERVOUS SYSTEM TUMORS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi278–vi279, https://doi.org/10.1093/neuonc/noy148.1159
CADD-15. TRANSLATIONAL DISCOVERY OF THERAPEUTIC TARGETS FOR GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi279, https://doi.org/10.1093/neuonc/noy148.1160
CADD-17. CT-179: AN INHIBITOR OF THE OLIG2 TRANSCRIPTION FACTOR WITH POTENT ANTI-TUMOUR ACTIVITY IN BRAIN CANCER
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi279, https://doi.org/10.1093/neuonc/noy148.1162
CADD-18. MP-Pt(IV): A MAOB SENSITIVE MITOCHONDRIAL SMART BOMB FOR TREATING GLIOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi279, https://doi.org/10.1093/neuonc/noy148.1163
CADD-28. MELATONIN: TARGETING THE CELL’S POWERHOUSE TO FIGHT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi280–vi281, https://doi.org/10.1093/neuonc/noy148.1169
CADD-30. A TREATMENT SIMULATOR FOR BRAIN CHEMOTHERAPY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi281, https://doi.org/10.1093/neuonc/noy148.1170
CADD-33. PERSONALIZED PHARMACOGENOMICS USING GLIOMA PATIENT-DERIVED ORTHOTOPIC XENOGRAFTS (PDOXS)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi281–vi282, https://doi.org/10.1093/neuonc/noy148.1173
CADD-48. microRNA-34a PACKAGED IN BACTERIAL NANOCELLS OVERCOMES THERAPEUTIC RESISTANCE IN GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi282, https://doi.org/10.1093/neuonc/noy148.1176
CADD-49. IDENTIFICATION AND VALIDATION OF AZOLES AS HK2 INHIBITORS IN GLIOBLASTOMA IN VITRO AND IN VIVO
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi282, https://doi.org/10.1093/neuonc/noy148.1177
CADD-53. GLIOBLASTOMA TUMORIGENESIS – LESSONS FROM REPRODUCTIVE IMMUNOLOGY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi283, https://doi.org/10.1093/neuonc/noy148.1179
CADD-56. INTRA-ARTERIAL NEO100 TRANSIENTLY OPENS THE BLOOD BRAIN BARRIER
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi283, https://doi.org/10.1093/neuonc/noy148.1181
CADD-58. PRECLINICAL DEVELOPMENT OF miR-10b ANTAGONIST FOR THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi284, https://doi.org/10.1093/neuonc/noy148.1183
Adult Clinical Trials – Immunologic
ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi2, https://doi.org/10.1093/neuonc/noy148.004
ATIM-10. A PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS CMV-SPECIFIC CYTOTOXIC T CELLS (CMV-TC) FOR GLIOBLASTOMA: DOSE ESCALATION AND CORRELATIVE RESULTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi2–vi3, https://doi.org/10.1093/neuonc/noy148.006
ATIM-13. ASUNERCEPT PLUS RADIOTHERAPY IN RELAPSED GLIOBLASTOMA. UPDATE ON FIVE YEARS OVERALL SURVIVAL OF STUDY NCT01071837 AND DEVELOPMENT OF A POPULATION-PK - TUMOR GROWTH INHIBITION - SURVIVAL MODEL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi3, https://doi.org/10.1093/neuonc/noy148.008
ATIM-14. CMV gB/pp65 eVLPs FORMULATED WITH GM-CSF AS A THERAPEUTIC VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi3, https://doi.org/10.1093/neuonc/noy148.009
ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi3–vi4, https://doi.org/10.1093/neuonc/noy148.010
ATIM-18. A PHASE I TRIAL OF VACCINATION WITH AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE DERIVED FROM AN ALLOGENEIC GLIOBLASTOMA STEMLIKE CELL LINE FOR PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi4, https://doi.org/10.1093/neuonc/noy148.013
ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi7, https://doi.org/10.1093/neuonc/noy148.024
ATIM-31. PHASE I STUDY OF TUMOR TREATMENT FIELDS AND A PERSONALIZED MUTATION-DERIVED TUMOR VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi8, https://doi.org/10.1093/neuonc/noy148.026
ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi8, https://doi.org/10.1093/neuonc/noy148.027
ATIM-34. TARGETING THE CD200 CHECKPOINT FOR THE FIGHT AGAINST CENTRAL NERVOUS SYSTEM TUMORS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi9, https://doi.org/10.1093/neuonc/noy148.029
ATIM-35. VXM01 PHASE I STUDY IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA – FINAL RESULTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi9, https://doi.org/10.1093/neuonc/noy148.030
ATIM-37. SAFETY RUN-IN RESULTS OF A PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO; aPDL1) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi9–vi10, https://doi.org/10.1093/neuonc/noy148.032
ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi10, https://doi.org/10.1093/neuonc/noy148.033
ATIM-40. HIGH RATE OF OBJECTIVE ANTI-TUMOR RESPONSE IN 9 PATIENTS WITH GLIOBLASTOMA AFTER VIRO-IMMUNOTHERAPY WITH ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB AND PD-1 CHECKPOINT BLOCKADE
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi10, https://doi.org/10.1093/neuonc/noy148.035
ATIM-41. PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) For Newly Diagnosed Glioblastoma
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi10–vi11, https://doi.org/10.1093/neuonc/noy148.036
ATIM-02. TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA IN A PHASE 2 STUDY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi1, https://doi.org/10.1093/neuonc/noy148.000
ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi1–vi2, https://doi.org/10.1093/neuonc/noy148.002
ATIM-06. PHASE 2 TRIAL OF SL-701 + BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA (GBM) MEETS PRIMARY ENDPOINT OF OS-12, WITH PRELIMINARY CORRELATION BETWEEN LONG-TERM SURVIVAL AND TARGET-SPECIFIC CD8+ T CELL IMMUNE RESPONSE
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi2, https://doi.org/10.1093/neuonc/noy148.003
ATIM-08. A PHASE I TRIAL OF PEMBROLIZUMAB AND VORINOSTAT COMBINED WITH TEMOZOLOMIDE AND RADIATION THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA (NCT03426891)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi2, https://doi.org/10.1093/neuonc/noy148.005
ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi3, https://doi.org/10.1093/neuonc/noy148.007
ATIM-19. RESULTS OF THE GLOBE STUDY: A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi4–vi5, https://doi.org/10.1093/neuonc/noy148.014
ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi5, https://doi.org/10.1093/neuonc/noy148.015
ATIM-21. UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi5, https://doi.org/10.1093/neuonc/noy148.016
ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi6, https://doi.org/10.1093/neuonc/noy148.018
ATIM-28. PHASE 2 STUDY OF ERC1671 PLUS BEVACIZUMAB VS BEVACIZUMAB PLUS PLACEBO IN RECURRENT GBM INTERIM RESULTS AND CORRELATIONS WITH CD4+ T LYMPHOCYTE COUNTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi7, https://doi.org/10.1093/neuonc/noy148.023
ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi10, https://doi.org/10.1093/neuonc/noy148.034
ATIM-42. SAFETY AND EFFICACY OF AUTOLOGOUS DENDRITIC CELLS/TUMOR CELL ANTIGEN ADJUVANT THERAPY OF GLIOBLASTOMA MULTIFORME: RESULTS OF 59 CASES
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi11, https://doi.org/10.1093/neuonc/noy148.037
ATIM-03. TTFIELDS AND PULSED BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA: A PHASE 2 STUDY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi1, https://doi.org/10.1093/neuonc/noy148.001
ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi4, https://doi.org/10.1093/neuonc/noy148.011
ATIM-17. PEMBROLIZUMAB BLOCKS PD-1 ON CAR T CELLS ADMINISTERED INTRAVENTRICULARLY TO GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi4, https://doi.org/10.1093/neuonc/noy148.012
ATIM-22. PROGNOSTIC VALUE OF PTEN LOSS IN NEWLY DIAGNOSED GBM PATIENTS TREATED WITH AUTOLOGOUS HEAT SHOCK PROTEIN VACCINE
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi5–vi6, https://doi.org/10.1093/neuonc/noy148.017
ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi6, https://doi.org/10.1093/neuonc/noy148.019
ATIM-25. NEOADJUVANT PD-1 ANTIBODY BLOCKADE IS ASSOCIATED WITH FOCAL UPREGULATION OF PD-L1 AND CD8 T CELL INFILTRATE IN RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi6, https://doi.org/10.1093/neuonc/noy148.020
ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi6–vi7, https://doi.org/10.1093/neuonc/noy148.021
ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi7, https://doi.org/10.1093/neuonc/noy148.022
ATIM-30. HOW TO MONITOR IMMUNOGENIC CELL DEATH IN PATIENTS WITH GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi7–vi8, https://doi.org/10.1093/neuonc/noy148.025
ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi8–vi9, https://doi.org/10.1093/neuonc/noy148.028
ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi9, https://doi.org/10.1093/neuonc/noy148.031
Adult Clinical Trials – Non-Immunologic
ACTR-07. COMPLETE, DURABLE RESPONSE OF A RECURRENT UNRESECTABLE GRADE III GLIOMA TO A REPURPOSED DRUG REGIMEN
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi12, https://doi.org/10.1093/neuonc/noy148.042
ACTR-08. A PHASE II STUDY OF APATINIB PLUS TEMOZOLOMIDE IN ADULTS WITH REFRACTORY RECURRENT HIGH-GRADE GLIOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi12, https://doi.org/10.1093/neuonc/noy148.043
ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi12–vi13, https://doi.org/10.1093/neuonc/noy148.044
ACTR-12. PRELIMINARY SAFETY AND EFFICACY OF A PHASE II TRIAL OF 18F-DOPA PET-GUIDED, DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi13, https://doi.org/10.1093/neuonc/noy148.046
ACTR-19. A MULTICENTER PILOT PHASE II STUDY OF CONTINUING TMZ WITH THE ADDITION OF DISULFIRAM AND COPPER FOR REFRACTORY GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi15, https://doi.org/10.1093/neuonc/noy148.053
ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 – FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi15, https://doi.org/10.1093/neuonc/noy148.054
ACTR-21. MANAGEMENT OF OCULAR SIDE EFFECTS IN PATIENTS WITH EGFR-AMPLIFIED GLIOBLASTOMA RECEIVING DEPATUXIZUMAB MAFODOTIN
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi15–vi16, https://doi.org/10.1093/neuonc/noy148.055
ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi16–vi17, https://doi.org/10.1093/neuonc/noy148.059
ACTR-29. KETOGENIC DIETS AS AN ADJUVANT THERAPY IN GLIOBLASTOMA (KEATING): A MIXED METHOD APPROACH TO ASSESSING TRIAL FEASIBILITY.
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi17, https://doi.org/10.1093/neuonc/noy148.062
ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi18–vi19, https://doi.org/10.1093/neuonc/noy148.066
ACTR-37. SHORT-TERM BEVACIZUMAB FOR RECURRENT GLIOBLASTOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi19–vi20, https://doi.org/10.1093/neuonc/noy148.070
ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi21, https://doi.org/10.1093/neuonc/noy148.075
ACTR-46. HIGHER DOSES OF TTFIELDS IN THE TUMOR ARE ASSOCIATED WITH IMPROVED PATIENT OUTCOME
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi21–vi22, https://doi.org/10.1093/neuonc/noy148.078
ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi22, https://doi.org/10.1093/neuonc/noy148.079
ACTR-48. FEASIBILITY OF DISCONTINUATION OF ADJUVANT TEMOZOLOMIDE AFTER 12 CYCLES REMAINING WITHOUT PROGRESSION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi22, https://doi.org/10.1093/neuonc/noy148.080
ACTR-49. PriCoTTF: A PHASE I/II TRIAL OF TUMOR TREATING FIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi22–vi23, https://doi.org/10.1093/neuonc/noy148.081
ACTR-58. TREATMENT OUTCOMES OF STEREOTACTIC RADIOTHERAPY COMBINED WITH BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi24, https://doi.org/10.1093/neuonc/noy148.089
ACTR-59. IMPROVING THE INTRA-OPERATIVE DIAGNOSIS OF HIGH-GRADE GLIOMA USING A FLUORESCENCE BIOMARKER – RESULT OF THE GALA-BIDD STUDY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi24–vi25, https://doi.org/10.1093/neuonc/noy148.090
ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi25, https://doi.org/10.1093/neuonc/noy148.091
ACTR-62. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi25, https://doi.org/10.1093/neuonc/noy148.092
ACTR-64. OBJECTIVE RESPONSES TO CHEMOTHERAPY IN RECURRENT GLIOMA DO NOT PREDICT BETTER SURVIVAL: A PROSPECTIVE ANALYSIS FROM THE GERMAN GLIOMA NETWORK
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi26, https://doi.org/10.1093/neuonc/noy148.094
ACTR-65. INTRATHECAL PEMETREXED FOR PATIENTS WITH RECURRENT LEPTOMENINGEAL METASTASIS FROM LUNG ADENOCARCINOMA: A PHASE I CLINICAL TRIAL (IPRLM,NCT03101579)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi26, https://doi.org/10.1093/neuonc/noy148.095
ACTR-66. BEVACIZUMAB THERAPY FOR THE TREATMENT OF ADULT GLIOBLASTOMA: SYSTEMATIC REVIEW & META-ANALYSIS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi26, https://doi.org/10.1093/neuonc/noy148.096
ACTR-71. PHASE 1/2 STUDY OF DIANHYDROGALACTITOL (VAL-083) WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi27, https://doi.org/10.1093/neuonc/noy148.101
ACTR-68. INITIAL TREATMENT OF GBM WITH A KETOGENIC DIET ALONG WITH RADIATION AND CHEMOTHERAPY: FEASIBILITY, TOXICITY AND RESPONSE
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi27, https://doi.org/10.1093/neuonc/noy148.098
ACTR-69. BLOOD DERIVED EXOSOMAL hTERT mRNA - A POTENTIAL BIOMARKER FOR GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi27, https://doi.org/10.1093/neuonc/noy148.099
ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi14, https://doi.org/10.1093/neuonc/noy148.049
ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi14, https://doi.org/10.1093/neuonc/noy148.050
ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi15, https://doi.org/10.1093/neuonc/noy148.052
ACTR-23. SAFETY OF INTRA-ARTERIAL CHEMOTHERAPY WITH OSMOTIC OPENING OF THE BLOOD-BRAIN BARRIER
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi16, https://doi.org/10.1093/neuonc/noy148.057
ACTR-27. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi17, https://doi.org/10.1093/neuonc/noy148.060
ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi17, https://doi.org/10.1093/neuonc/noy148.061
ACTR-32. 5-ALA FLUORESCENCE IS A POWERFUL MARKER FOR DETECTION OF UNEXPECTED GLIOBLASTOMA TISSUE DURING SURGERY OF RADIOLOGICALLY SUSPECTED LOW-GRADE GLIOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi18, https://doi.org/10.1093/neuonc/noy148.065
ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi19, https://doi.org/10.1093/neuonc/noy148.067
ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi19, https://doi.org/10.1093/neuonc/noy148.069
ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX–M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi20, https://doi.org/10.1093/neuonc/noy148.072
ACTR-42. THE USE OF ADVANCED DIFFUSION MRI PARAMETERS IN THE ASSESSMENT OF TREATMENT RESPONSE IN GLIOBLASTOMA USING MULTI-B VALUE ACQUISITION AND A HISTOGRAM-BASED APPROACH
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi20–vi21, https://doi.org/10.1093/neuonc/noy148.074
ACTR-44. PRELIMINARY RESULTS FROM THE NCT02770378 PROOF-OF-CONCEPT CLINICAL TRIAL ASSESSING THE SAFETY OF THE CUSP9v3 PROTOCOL COMBINED WITH METRONOMIC TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi21, https://doi.org/10.1093/neuonc/noy148.076
ACTR-45. PHASE 0/2 STUDY OF RIBOCICLIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi21, https://doi.org/10.1093/neuonc/noy148.077
ACTR-50. EFFECT OF CONCURRENT AND ADJUVANT TEMOZOLOMIDE ON SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS WITHOUT 1p/19q CO-DELETION: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY (INTERIM RESULTS FROM THE KNOG-1101 STUDY)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi23, https://doi.org/10.1093/neuonc/noy148.082
ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi23, https://doi.org/10.1093/neuonc/noy148.083
ACTR-53. STEAM / EORTC 1608: STUDY OF TG02 IN ELDERLY NEWLY DIAGNOSED OR ADULT RELAPSED PATIENTS WITH ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA - A PHASE 1B STUDY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi23–vi24, https://doi.org/10.1093/neuonc/noy148.085
ACTR-57. RELATIVE CEREBRAL BLOOD VOLUME (RCBV) AS RESPONSE PREDICTOR IN THE TREATMENT OF RECURRENT GLIOBLASTOMA (GB) WITH ANTIANGIOGENIC THERAPY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi24, https://doi.org/10.1093/neuonc/noy148.088
ACTR-72. IDH-WILD TYPE GRADE II GLIOMAS: A RETROSPECTIVE SERIES OF ITALIAN ASSOCIATION OF NEURO-ONCOLOGY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi27–vi28, https://doi.org/10.1093/neuonc/noy148.102
ACTR-67. A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN (ONIVYDE) USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS: RESULTS THUS FAR
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi26–vi27, https://doi.org/10.1093/neuonc/noy148.097
ACTR-70. INCREASING SURVIVAL IN BIOPSY-ONLY GBM PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi27, https://doi.org/10.1093/neuonc/noy148.100
ACTR-01. SAFETY ANALYSES OF TUMOR TREATING FIELDS IN COMBINATION WITH LOMUSTINE IN THE EF14 PHASE 3 CLINICAL STUDY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi11, https://doi.org/10.1093/neuonc/noy148.038
ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi11, https://doi.org/10.1093/neuonc/noy148.039
ACTR-03. A FEASIBILITY TRIAL OF THE MODIFIED ATKINS DIET AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi11–vi12, https://doi.org/10.1093/neuonc/noy148.040
ACTR-06. INITIAL RESULTS OF A PHASE I STUDY OF PROCASPASE ACTIVATING CCOMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE FOR RECURRENT MALIGNANT GLIOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi12, https://doi.org/10.1093/neuonc/noy148.041
ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi13, https://doi.org/10.1093/neuonc/noy148.045
ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi13, https://doi.org/10.1093/neuonc/noy148.047
ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi13–vi14, https://doi.org/10.1093/neuonc/noy148.048
ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi14–vi15, https://doi.org/10.1093/neuonc/noy148.051
ACTR-22. A PHASE I STUDY OF CYTOSINE DEAMINASE-EXPRESSING NEURAL STEM CELLS (CD-NSCs) ADMINISTERED INTRACRANIALLY AND IN COMBINATION WITH ORAL 5-FLUOROCYTOSINE (5-FC) AND LEUCOVORIN IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi16, https://doi.org/10.1093/neuonc/noy148.056
ACTR-25. UPDATED RESULTS FROM A PROSPECTIVE, RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi16, https://doi.org/10.1093/neuonc/noy148.058
ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi17–vi18, https://doi.org/10.1093/neuonc/noy148.063
ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi18, https://doi.org/10.1093/neuonc/noy148.064
ACTR-35. MOLECULAR MATCHMAKING: EFFICACY OF EARLY CLINICAL TRIALS GUIDED BY NEXT-GENERATION SEQUENCING IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi19, https://doi.org/10.1093/neuonc/noy148.068
ACTR-38. A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi20, https://doi.org/10.1093/neuonc/noy148.071
ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi20, https://doi.org/10.1093/neuonc/noy148.073
ACTR-52. TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) IN THE EF-14 PHASE 3 CLINICAL STUDY – A SAFETY ANALYSIS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi23, https://doi.org/10.1093/neuonc/noy148.084
ACTR-54. PATTERN OF RECURRENCE AND IMPACT ON SURVIVAL OF SALVAGE THERAPIES IN LOW-GRADE GLIOMAS FOLLOWING DOSE-DENSE TEMOZOLOMIDE
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi24, https://doi.org/10.1093/neuonc/noy148.086
ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi24, https://doi.org/10.1093/neuonc/noy148.087
ACTR-63. TREATMENT AND SURVIVAL OF PATIENTS WITH LOWER GRADE GLIOMA ACCORDING TO THE 2007 AND THE 2016 WHO CLASSIFICATION: A RETROSPECTIVE ANALYSIS OF 423 PATIENTS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi25–vi26, https://doi.org/10.1093/neuonc/noy148.093
Angiogenesis and Invasion
ANGI-02. A CRITICAL ROLE FOR LARG IN RhoC MEDIATED GLIOBLASTOMA CELL INVASION
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi28, https://doi.org/10.1093/neuonc/noy148.104
ANGI-14. EPIGENETIC REACTIVATION OF BAI1 SUPPRESSES TUMOR INVASION BY PREVENTING TGFβ1-INDUCED MESENCHYMAL SWITCH IN GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi31, https://doi.org/10.1093/neuonc/noy148.115
ANGI-11. TUMOR TREATING FIELDS (TTFIELDS) INHIBIT CANCER CELL MIGRATION AND INVASION BY INDUCING REORGANIZATION OF THE ACTIN CYTOSKELETON AND FORMATION OF CELL ADHESIONS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi30, https://doi.org/10.1093/neuonc/noy148.112
ANGI-15. PDGF-MEDIATED MESENCHYMAL TRANSFORMATION RENDERS ENDOTHELIAL RESISTANCE TO ANTI-VEGF TREATMENT IN GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi31, https://doi.org/10.1093/neuonc/noy148.116
ANGI-17. INTERLEUKIN 1 SIGNALING REGULATES BLOOD-BRAIN BARRIER INTEGRITY IN GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi31–vi32, https://doi.org/10.1093/neuonc/noy148.118
ANGI-07. 5ALA FLUORESCENCE BASED SORTING IDENTIFIES SERPINE1 AS A NOVEL THERAPEUTIC TARGET ON INVASIVE GBM CELLS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi29, https://doi.org/10.1093/neuonc/noy148.108
ANGI-09. CIRCULATING MIR-10B AND MIR-21 IN PATIENTS WITH GBM TREATED WITH BEVACIZUMAB ARE SECRETED TO THE CIRCULATION BY PROTEINS AND THEIR HIGH QUANTIFICATION IS PROBABLY THE RESULT OF DRUG-INDUCED TUMOR HYPOXIA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi30, https://doi.org/10.1093/neuonc/noy148.110
ANGI-01. CORRELATION BETWEEN HISTOLOGICAL AND MRI MEASURES OF INFILTRATION IN A PRECLINICAL GLIOBLASTOMA MODEL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi28, https://doi.org/10.1093/neuonc/noy148.103
ANGI-13. TENASCIN-C INDUCES VASCULOGENIC MIMICRY FORMATION IN GLIOBLASTOMA THROUGH AKT PATHWAY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi30–vi31, https://doi.org/10.1093/neuonc/noy148.114
ANGI-06. THE MATRIX PROTEIN THROMBOSPONDIN-1 IS A DOWNSTREAM TARGET OF TGF-β INDUCED MICROTUBE FORMATION IN GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi29, https://doi.org/10.1093/neuonc/noy148.107
ANGI-18. AUTOCRINE CYCLE OF BONE MORPHOGENETIC PROTEIN 4 (BMP4) ENHANCES TUMOR AGGRESSIVENESS IN IDH1-MUTATED GLIOMAS
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi32, https://doi.org/10.1093/neuonc/noy148.119
